Evaxion reports promising phase 2 trial results for cancer vaccine - Investing.com
Evaxion Biotech's phase 2 trial of EVX-01, a personalized cancer vaccine, showed a 69% Overall Response Rate in advanced melanoma patients. The AI-Immunology™ platform-designed vaccine targets neoantigens, triggering a targeted immune response in 79% of cases. With melanoma cases projected to reach 510,000 by 2040, EVX-01's potential market value is significant. Final trial results are expected in Q3 2025.
Reference News
Evaxion Biotech's phase 2 trial of EVX-01, a personalized cancer vaccine, showed a 69% Overall Response Rate in advanced melanoma patients. The AI-Immunology™ platform-designed vaccine targets neoantigens, triggering a targeted immune response in 79% of cases. With melanoma cases projected to reach 510,000 by 2040, EVX-01's potential market value is significant. Final trial results are expected in Q3 2025.